Journal Scans
Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
Olaparib and Pegylated Liposomal Doxorubicin: Similar Outcomes in Advanced BRCA1- or BRCA2-Mutated Ovarian Cancer
S Kaye, J Lubinski, U Matulonis, J Ern Ang, C Gourley, B Karlan, A Amnon, K Bell-McGuinn, L Chen, M Friedlander, T Safra, I Vergote, M Wickens, E Lowe, J Carmichael, B Kaufman
20111127
2011 Dec 27
J Clin Oncol
Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
J Clin Oncol. 2011 Dec 27;[Epub Ahead of Print], S Kaye, J Lubinski, U Matulonis, J Ern Ang, C Gourley, B Karlan, A Amnon, K Bell-McGuinn, L Chen, M Friedlander, T Safra, I Vergote, M Wickens, E Lowe, J Carmichael, B Kaufman
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Few treatment options are available for patients with BRCA1- or BRCA2-mutated ovarian cancer. The poly(ADP-ribose) polymerase inhibitor olaparib may cause selective cell death in cells that have lost BRCA1 or BRCA2 function. Previous studies have demonstrated responses in patients with BRCA1/BRCA2-mutated ovarian cancer treated with olaparib. Pegylated liposomal doxorubicin (PLD), which has been approved for treatment of ovarian cancer that has progressed or recurred after platinum-based therapy,...
